Pharma Focus Europe

PharmAlliance's Acquisition of CHEORS Marks a Strategic Step Forward in Pharmaceutical Expansion

Tuesday, April 16, 2024

PharmAlliance, a prominent pharmaceutical and life sciences services platform, is thrilled to announce its latest acquisition of Complete Health Economics Outcomes Research Solutions (CHEORS), a leading provider of health economics and outcomes research (HEOR) and market access services across the pharmaceutical, biotechnology, and medical device industries. This acquisition marks a significant milestone for PharmAlliance as it strengthens its global presence and enhances its capabilities in launch and commercialization.

CHEORS represents the third strategic acquisition for PharmAlliance, a portfolio company of Waud Capital Partners. PharmAlliance initiated its acquisition journey with BioBridges, a reputable provider of clinical development services, in August 2023. Subsequently, it acquired Monitorforhire (MFH), now a division of BioBridges, in late 2023, thereby expanding its specialized service offerings to clients and its network of over 4,000 clinical research professionals worldwide.

Mark Bouck, Chairman & CEO of PharmAlliance and BioBridges, expressed his enthusiasm about the addition of CHEORS to the portfolio, stating, “CHEORS’ outstanding reputation and innovative approach represent a crucial advancement for the PharmAlliance portfolio. Their global capabilities and expertise in HEOR/RWE services underscore our dedication to furnishing comprehensive solutions to our clients in drug and device development.”

Specializing in economic modeling, health technology assessment (HTA) submissions, evidence synthesis, and real-world evidence (RWE) analysis, CHEORS addresses the burgeoning demand for HEOR activities throughout the drug development lifecycle, from early stages to reimbursement and beyond. Known for its exceptional customer satisfaction and technical proficiency, CHEORS brings a history of robust organic growth in HEOR and RWE domains.

Shalini Bagga, PhD, President of CHEORS, highlighted the synergies between CHEORS and PharmAlliance, emphasizing their shared values and collective expertise across biotech and pharma sectors. Bagga remarked, “Together, we offer an expanded array of high-quality services, poised to accelerate the delivery of transformative treatments to patients. This alliance positions us to make a significant impact in the industry.”

 

Source: businesswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva